Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 5/20 | 0.63 |
| ▸ | RORC | P51449 | 4/20 | 0.45 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.40 |
| ▸ | GPR27 | Q9NS67 | 2/20 | 0.40 |
| ▸ | PNLIP | P16233 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.36 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.36 |
| ▸ | IDH1 | O75874 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2357191 | 0.93 | NR3C2 (0.58) | NR3C2RORCAVPR2GPR27PNLIP | |
| SCHEMBL27997700 | 0.90 | NR3C2 (0.78) | NR3C2RORCAVPR2GPR27CNR2 | |
| SCHEMBL2359197 | 0.90 | NR3C2 (0.78) | NR3C2RORCAVPR2GPR27CNR2 | |
| SCHEMBL2547117 | 0.89 | NR3C2 (0.58) | NR3C2RORCAVPR2GPR27PNLIP | |
| SCHEMBL2359248 | 0.88 | NR3C2 (0.81) | NR3C2RORCAVPR2GPR27ALDH1A1 | |
| SCHEMBL27997696 | 0.88 | NR3C2 (0.81) | NR3C2RORCAVPR2GPR27ALDH1A1 | |
| SCHEMBL2358996 | 0.82 | NR3C2 (0.62) | NR3C2AVPR2ALDH1A1 | |
| SCHEMBL2543882 | 0.82 | NR3C2 (0.52) | NR3C2PNLIPKCNK3KCNK9 | |
| SCHEMBL2358756 | 0.81 | NR3C2 (0.66) | NR3C2RORCALDH1A1 | |
| SCHEMBL2551383 | 0.81 | NR3C2 (0.74) | NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642640-B2 | 1-phenylpyrrole derivatives | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642640-B2 | 1-phenylpyrrole derivatives | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642640-B2 | 1-phenylpyrrole derivatives | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2349996-B1 | 1-PHENYLPYRROLE COMPOUNDS | EXELIXIS INC (US) | 2014-01-01 | — | — | EP | disclosed |
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2349996-A1 | 1-PHENYLPYRROLE COMPOUNDS | Exelixis, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010042626-A1 | 1-PHENYLPYRROLE COMPOUNDS | EXELIXIS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | REN, AGTR1, NR3C2 | NR3C2 3/4885RORC 2039/4885AVPR2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.